Tissue distribution and integrated pharmacokinetic properties of major effective constituents of oral Gegen-Qinlian decoction in mice

Jingze Lu, Dandan Hong, Dan Ye, Sheng Mu, Rong Shi, Yu Song, Chu Feng, Bing‐Liang MaFrontiers in Pharmacology 2022 · DOI

TL;DR

This study developed a sensitive LC-MS/MS method to track multiple compounds from the traditional Chinese medicine Gegen-Qinlian decoction (GQD) in mice. They found that key GQD components accumulate in the liver and colon, suggesting these are its primary target tissues for treating related diseases. An "integrated constituent" analysis revealed GQD's overall pharmacokinetic behavior, highlighting the colon as a particularly important site of action.

What Problem Does This Paper Address?

Traditional Chinese Medicine (TCM) formulas like Gegen-Qinlian decoction (GQD) are complex mixtures with known therapeutic benefits for conditions like ulcerative colitis and non-alcoholic fatty liver disease. However, understanding how these formulas work at a molecular level is challenging due to the sheer number of active compounds. Specifically, researchers need to know where these compounds go in the body (tissue distribution) and how their concentrations change over time (pharmacokinetics) to identify the truly "effective constituents" and understand the overall drug action. Previous studies often focused on individual compounds or limited sets, and lacked a comprehensive view of how the entire GQD formulation behaves in vivo, especially in its potential target organs. This paper aims to bridge this gap by simultaneously quantifying numerous GQD constituents in various tissues and developing an "integrated pharmacokinetic" approach to understand the formula's systemic behavior.

Methods

The core of this research lies in a sophisticated analytical technique: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The authors developed and validated a method capable of simultaneously detecting and quantifying 19 major GQD constituents in biological samples like plasma and tissue homogenates (liver and colon). This method was designed to be rapid, sensitive, and accurate.

Key steps included:

  • Sample Preparation: Plasma and tissue samples were meticulously prepared to extract the target compounds and remove interfering substances. This involved steps like centrifugation, drying, and reconstitution.
  • LC-MS/MS Analysis: Samples were injected into the LC-MS/MS system, which separates compounds based on their chemical properties (chromatography) and then identifies and quantifies them based on their mass-to-charge ratio and fragmentation patterns (mass spectrometry).
  • Pharmacokinetic Modeling: Concentration-time data from various tissues (portal vein, systemic circulation, liver, colon) were used to calculate pharmacokinetic parameters such as peak concentration (Cmax), time to peak concentration (Tmax), half-life (T1/2), and area under the curve (AUC).
  • Integrated Pharmacokinetics: A novel approach was employed where the pharmacokinetic profiles of individual constituents were combined using "weight coefficients" (based on their AUC values) to create an "integrated constituent" profile. This allowed for an overall assessment of the GQD's pharmacokinetic behavior.

Datasets

Not discussed in the paper. The study utilized biological samples (plasma, liver, and colon homogenates) from mice that were administered GQD.

Key Insights and Ideas

  • Target Tissue Identification: The study strongly suggests that the liver and colon are the primary target tissues for GQD. Specific compounds showed significantly higher concentrations in these organs compared to systemic circulation.
  • "Major Effective Constituents": By correlating high tissue exposure with known biological activities, the researchers identified key compounds responsible for GQD's effects on liver and colon diseases. For liver health, daidzein, baicalin, and baicalein are highlighted, while for colon health, puerarin, berberine, epiberberine, and others are implicated.
  • Colon as a Key Site: The "integrated constituent" analysis revealed that GQD accumulates in the colon to a much greater extent (approximately 10 times higher) than in the liver. This points towards the colon being a particularly crucial site for GQD's therapeutic action, especially for inflammatory intestinal diseases.
  • Integrated Pharmacokinetics for TCM: The development and application of the "integrated constituent" pharmacokinetic approach offer a valuable tool for understanding the complex behavior of multi-component TCMs, moving beyond the limitations of studying individual compounds.

Key Results

  • Tissue Distribution:
    • Liver: Daidzein, baicalin, and baicalein showed high exposure in the liver.
  • Colon: Puerarin, berberine, epiberberine, coptisine, palmatine, jatrorrhizine, magnoflorine, glycyrrhizic acid, and glycyrrhetinic acid were significantly enriched in the colon.
  • Integrated Pharmacokinetics:
    • The "integrated constituent" reached peak concentration at 4.0 hours in all measured compartments (portal vein, systemic circulation, liver, and colon).
  • Half-lives (T1/2) ranged from 1.5 to 4.1 hours, and mean retention times (MRT) were between 4.5 and 6.3 hours.
  • The concentration of the "integrated constituent" in the colon was approximately 10 times higher than in the liver, and both were significantly higher than in systemic circulation.

Limitations and Future Work

  • Incomplete Elimination: The authors acknowledge that in some cases, constituents in the colon and liver were not completely eliminated within the 24-hour observation period. This might affect the precise calculation of half-life values in these tissues.
  • "Integrated Constituent" Interpretation: While the integrated pharmacokinetic approach is powerful, the authors note that it doesn't inherently distinguish the specific efficacy of each constituent. They suggest future work could incorporate "pharmacodynamic weighting coefficients" to better link pharmacokinetic profiles with specific pharmacological effects.
  • Complex Diseases: Applying this modified integrated pharmacokinetic strategy to complex diseases like intestinal and liver diseases, where GQD is effective, will remain a challenge.
  • Further Validation: While the LC-MS/MS method was validated for plasma and partially for liver homogenates, further validation for colon samples might be beneficial.

Summary updated

Abstract

<i>Gegen-Qinlian</i> decoction (GQD) is a classic traditional Chinese medicine (TCM) formula. GQD is effective against colon or liver-related diseases including ulcerative colitis, non-alcoholic fatty liver, and type 2 diabetes. In this study, a liquid chromatography-tandem mass spectrometry method was developed, validated, and then applied to reveal the tissue distribution and integrated pharmacokinetic properties of major effective constituents of oral GQD in mice. The established method was quick, sensitive, and accurate enough to analyze GQD constituents in plasma and tissue homogenate samples quantitatively. According to their concentrations in the portal vein, systemic circulation, liver and colon samples of the mice after oral administration of GQD, the concentration-time curves of the constituents were respectively plotted. The results showed that daidzein, baicalin, and baicalein had relatively high exposure levels in the livers, while puerarin, berberine, epiberberine, coptisine, palmatine, jatrorrhizine, magnoflorine, glycyrrhizic acid, and glycyrrhetinic acid were enriched in the colons. Given that these constituents have significant biological activity, they could be regarded as the major effective constituents of GQD in treating colon or liver-related diseases, respectively. In addition, the integrated pharmacokinetic properties of GQD were studied. The GQD "integrated constituent" reached peak concentration at 4.0 h in the portal vein, the systemic circulation, the livers, and the colons, with half-lives of 1.5-4.1 h and mean retention time of 4.5-6.3 h, respectively. Furthermore, the concentration of the GQD "integrated constituent" in the colons was approximately 10 times higher than that in the livers, both of which were much higher than that in the systemic circulation, indicating its accumulation in these tissues, especially in the colons. In conclusion, the tissue distribution and integrated pharmacokinetic properties of oral GQD were revealed in the study. The results of the tissue distribution study would contribute to identifying the major target tissues and effective constituents of GQD, while the results of the integrated pharmacokinetic study would help to explain the pharmacokinetic properties of oral GQD as a whole.
BibTeX
@inproceedings{lu2022tissue,
  author = {Jingze Lu and Dandan Hong and Dan Ye and Sheng Mu and Rong Shi and Yu Song and Chu Feng and Bing‐Liang Ma},
  title = {{Tissue distribution and integrated pharmacokinetic properties of major effective constituents of oral Gegen-Qinlian decoction in mice}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.996143},
}
Figure